Modality
Nanobody
MOA
PD-L1i
Target
PD-1
Pathway
PD-1/PD-L1
UCHuntington's
Development Pipeline
Preclinical
~Jun 2014
→ ~Sep 2015
Phase 1
~Dec 2015
→ ~Mar 2017
Phase 2
~Jun 2017
→ ~Sep 2018
Phase 3
Dec 2018
→ Sep 2031
Phase 3Current
NCT08288723
1,743 pts·Huntington's
2025-09→2031-09·Terminated
NCT08118245
1,701 pts·UC
2018-12→2030-01·Recruiting
NCT07843317
249 pts·Huntington's
2024-02→2028-11·Active
+1 more trial
5,260 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (4)
2028-11-102.6y awayPh3 Readout· Huntington's
2029-07-243.3y awayPh3 Readout· UC
2030-01-273.8y awayPh3 Readout· UC
2031-09-255.5y awayPh3 Readout· Huntington's
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P3
Recruit…
P3
Active
P3
Active
P3
Termina…
Catalysts
Ph3 Readout
2028-11-10 · 2.6y away
Huntington's
Ph3 Readout
2029-07-24 · 3.3y away
UC
Ph3 Readout
2030-01-27 · 3.8y away
UC
Ph3 Readout
2031-09-25 · 5.5y away
Huntington's
RecruitingActiveTerminated|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08288723 | Phase 3 | Huntington's | Terminated | 1743 | VA |
| NCT08118245 | Phase 3 | UC | Recruiting | 1701 | DOR |
| NCT07843317 | Phase 3 | Huntington's | Active | 249 | CfB |
| NCT03786509 | Phase 3 | UC | Active | 1567 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| MRN-8133 | Moderna | Phase 2 | PD-1 | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| Miriglumide | Alnylam | Phase 3 | CD3 |